Researchers at Mass General Brigham and the Broad Institute have employed CRISPR screening to identify gene knockouts that improve T cell function and persistence in chimeric antigen receptor (CAR) T therapies targeting multiple myeloma. The study found deletion of the cell cycle regulator CDKN1B enhances CAR T cell proliferation, longevity, and antitumor activity. This systematic approach accelerates the identification of genetic modifications that may boost therapeutic efficacy and durability, with implications for improving cancer immunotherapy outcomes.